TerminatedPhase 4

Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases

Stopped: Low Accrual

United States10 participantsStarted 2021-06-22

Plain-language summary

If an abbreviated hepatobiliary phase (HBP) protocol liver MR with gadobenate dimeglumine is shown clinically comparable to standard of care liver MR with gadoxetate disodium for detecting hepatic metastasis from colorectal cancer, its use will save time, cost, and patients' effort.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Colorectal cancer patients * Age 18-80 years * No prior treatment including surgery * Prior imaging with suspected liver metastasis Exclusion Criteria: * Age \< 18 years or \> 80 years * eGFR \< 30 ml/min/1.73 m2 * Previous reaction to gadolinium contrast agents * History of claustrophobia or movement disorders likely to impact image quality * Non-MR safe implants or metallic foreign bodies

What they're measuring

Diagnostic Performance of gadobenate dimeglumine

Timeframe: 1 month

Quantitative Measures of hepatobiliary phase images

Timeframe: 1 month

Preference of radiologists for the images generated by amHBP versus aeHBP

Timeframe: 1 month

Trial details

NCT IDNCT04973007

SponsorUniversity of Colorado, Denver

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-05-06

View on ClinicalTrials.gov More Oligometastatic Disease trials